首页> 美国卫生研究院文献>Prostate International >Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/mL and negative digital rectal examination
【2h】

Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/mL and negative digital rectal examination

机译:前列腺健康指数在男性首次前列腺活检中的前列腺癌检测中的预期性能总前列腺特异性抗原为4–10 ng / mL直肠指检阴性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe disadvantage of using total serum prostatic specific antigen (PSA) test for detection of prostate cancer is that it has a low specificity. The low specificity of total PSA (tPSA) test leads to unnecessary prostate biopsies. In this prospective study, we assessed the serum tPSA, free PSA, p2PSA, and the Prostate Health Index (PHI) in the detection of prostate cancer in men with a tPSA of 4–10 ng/mL and a negative digital rectal examination (DRE).
机译:背景技术使用总血清前列腺特异性抗原(PSA)检测来检测前列腺癌的缺点是特异性低。总PSA(tPSA)测试的低特异性导致不必要的前列腺活检。在这项前瞻性研究中,我们评估了血清tPSA,游离PSA,p2PSA和前列腺健康指数(PHI)在tPSA为4–10 ng / mL且直肠指检阴性(DRE)的男性中检测前列腺癌)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号